Arcturus Therapeutics Holdings Inc. (ARCT)

NASDAQ: ARCT · USD

$12.1

+0.83 (+7.4%)· Recorded snapshot

Market cap	342.8M
Revenue (ttm)	29.4M
Net income (ttm)	-93.3M
EPS (ttm)	-$3.33
Shares out	28.4M
Volume	589,438
Beta	2.48

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 29.4M
Net income (ttm): -93.3M
EPS (ttm): -$3.33
Market cap: 342.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-46.3

P25 n/aP50 n/aP75 n/a

ROIC-2,828.9

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ARCT indicators

Market & fundamental data

Available fields

199

Groups with data

Currency

USD

Showing 199 of 199 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001768224
Company name	Arcturus Therapeutics Holdings Inc.
Country	United States
Country code	US
CUSIP number	03969T109
Earnings date	2026-11-05
Earnings time	amc
Employees	111
Employees change	-65
Employees growth	-36.93%
Enterprise value	$174.2M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2013
In index	RUSSELL2000
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US03969T1097
Last 10-K release date	2026-03-03
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$342.8M
Market cap category	Small-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$12.06
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ARCT
U.S. state	California
Website	https://arcturusrx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-27.59%
EV/Sales	5.77x
FCF / EV yield	-42.99%
FCF yield	-21.55%
Forward EV/Sales	9.44x
Forward P/S	18.83x
P/B ratio	1.86x
P/S ratio	11.51x
Price / tangible book value	1.97x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	-195.5%
Operating margin	-348.32%
Pretax margin	-317.62%
Profit per employee	$-840,324
Revenue per employee	$264,577
ROA	-23.96%
ROA (5Y)	-13.89%
ROCE	-53.62%
ROE	-46.31%
ROE (5Y)	-26.47%
ROIC	-2,828.93%
SBC / revenue	71.85%
Tax / revenue	-0.01%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth	-75.95%
Revenue growth (Q)	-89.55%
Revenue growth (QoQ)	43.57%
Revenue growth 3Y	-51.93%
Revenue growth 5Y	27.55%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-93,000
Depreciation and amortization	$2.7M
EBIT	$-102.3M
EBITDA	$-99.5M
EPS	$-3.33
FCF per share	$-2.56
Financing cash flow	$12.9M
Free cash flow	$-72.8M
Free cash flow minus SBC	$-93.9M
Gross profit	$-57.4M
Income taxes	$-4,000
Investing cash flow	$-41,000
Net cash flow	$-59.8M
Net income	$-93.3M
Operating cash flow minus SBC	$-93.8M
Operating income	$-102.3M
Revenue	$29.4M
Stock-based compensation	$21.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-0.68
Book value per share	$6.04
Debt / equity	0.13
Interest coverage	-11,366
Long-term assets	$27.1M
Long-term liabilities	$19M
Net cash (debt)	$168.6M
Net cash / market cap	49.87%
Net cash growth	-0.56%
Net debt / equity	-0.98
Piotroski F-Score	1
Property, plant and equipment	$25.1M
Shareholders' equity	$171.8M
Tangible book value	$171.8M
Tangible book value per share	$6.04
Total assets	$224.3M
Total cash	$191.5M
Total debt	$22.9M
Total liabilities	$52.5M
WACC	16.77%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.11
Current assets	$197.2M
Current liabilities	$33.5M
Current ratio	5.88
Net working capital	$-23.9M
Quick ratio	5.76
Working capital	$163.6M
Working capital turnover	0.15

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-3.47%
Dividend yield	0%
Shareholder yield	-3.47%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$9.49
1D price change	7.39%
1M price change	-12.92%
1M total return	-12.92%
1W price change	8.94%
1W total return	8.94%
1Y price change	13.88%
1Y return CAGR	13.89%
1Y total return	13.88%
20-day SMA	$11.84
200-day SMA	$8.96
3M price change	109.38%
3M total return	109.38%
3Y price change	-34.49%
3Y return CAGR	-13.15%
3Y total return	-34.49%
50-day SMA	$13.57
50-day SMA vs 200-day SMA	50over200
52-week high	$17.96
52-week high date	2026-09-17
52-week low	$5.50
52-week low date	2026-07-24
5Y price change	-73.51%
5Y return CAGR	-23.34%
5Y total return	-73.51%
6M price change	45.3%
6M total return	45.3%
All-time high	$129.71
All-time high date	2020-12-07
All-time low	$4.11
All-time low date	2018-12-28
Average true range (ATR)	$1.09
Average volume	651K
Beta (1Y)	2.12
Beta (2Y)	2.42
Beta (5Y)	2.48
Change from 52-week high	-32.85%
Change from 52-week low	119.27%
Change from all-time high	-90.7%
Change from all-time low	193.43%
Change from open	3.61%
Day's gap	3.65%
Dollar volume	$7.1M
High price	$12.21
Low price	$11.27
Monthly RSI	48.01
Open price	$11.64
Position in 52-week range	84.04%
Premarket change	0.36%
Premarket close	$11.23
Premarket price	$11.27
Premarket volume	201
Previous close	$11.23
Price vs 150-day SMA	27.13%
Price vs 20-day SMA	1.82%
Price vs 200-day SMA	34.57%
Price vs 50-day SMA	-11.15%
Relative volume	0.92
RSI	50.42
Sharpe ratio	0.49
Sharpe ratio (3Y)	0.21
Sharpe ratio (5Y)	0.11
Sortino ratio	0.91
Sortino ratio (3Y)	0.38
Sortino ratio (5Y)	0.23
Volume	589.4K
Weekly RSI	53.97
YTD price change	96.74%
YTD total return	96.74%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	26.2M
Float percentage	92.01%
Shares change (QoQ)	0.01%
Shares change (YoY)	3.47%
Shares held by insiders	7.99%
Shares held by institutions	75.41%
Shares outstanding	28.4M
Short % of float	20.56%
Short % of shares	18.92%
Short ratio	5.9 days

Deeper analysis on ARCT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ARCT report

Is a complete ARCT research report available?

No complete published report is available for Arcturus Therapeutics Holdings Inc. (ARCT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Arcturus Therapeutics Holdings Inc. (ARCT)

Price

Financial snapshot

Fair-value bridge

Latest news · ARCT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ARCT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ARCT

Frequently asked questions